Difference between revisions of "Stanisław Burzyński"

From Psiram
Jump to navigation Jump to search
 
Line 5: Line 5:
 
In 1993, Burzynski was brought to court in Texas for treating patients with a therapy not approved by the Food and Drug Administration (FDA) and for selling antineoplastons in interstate commerce.<ref name=opinion>[http://www.3rdcoa.courts.state.tx.us/opinions/HTMLopinion.asp?OpinionID=847 Texas State Board of Medical Examiners, Appellant v. Stanislaw R. Burzynski, M.D., Ph.D., Appellee] Court judgement</ref><ref name="openjurist1987"/> In 1998 the Texas Attorney General, Dan Morales, placed limits on his advertising of antineoplastons<ref>{{cite web | author = Texas Attorney General's Office | title = Limits Placed on Burzynski's Cancer Treatment | url = http://www.quackwatch.org/04ConsumerEducation/News/burzynski.html | date = 1998-02-10 | accessdate = 2007-05-10|format=courtesy copy}}</ref> and ordered him to cease and desist selling his products without FDA supervised clinical trials.<ref name=1994judgement/> Burzynski appealed the limitations on his advertising on the grounds of free speech, but the appeal court upheld the decision, stating that "Burzynski's commercial speech does not concern a lawful activity."<ref name=opinion/> Burzynski was also found guilty of fraud in 1994, as he claimed reimbursement from a [[health insurer]] for a cancer treatment administered illegally.<ref name=1994judgement>[ftp://www.ca5.uscourts.gov/pub/93/93-02071.CV0.wpd.pdf No. 93-2071] July 28, 1994. United States Court of Appeals, Fifth Circuit summary judgment.</ref>
 
In 1993, Burzynski was brought to court in Texas for treating patients with a therapy not approved by the Food and Drug Administration (FDA) and for selling antineoplastons in interstate commerce.<ref name=opinion>[http://www.3rdcoa.courts.state.tx.us/opinions/HTMLopinion.asp?OpinionID=847 Texas State Board of Medical Examiners, Appellant v. Stanislaw R. Burzynski, M.D., Ph.D., Appellee] Court judgement</ref><ref name="openjurist1987"/> In 1998 the Texas Attorney General, Dan Morales, placed limits on his advertising of antineoplastons<ref>{{cite web | author = Texas Attorney General's Office | title = Limits Placed on Burzynski's Cancer Treatment | url = http://www.quackwatch.org/04ConsumerEducation/News/burzynski.html | date = 1998-02-10 | accessdate = 2007-05-10|format=courtesy copy}}</ref> and ordered him to cease and desist selling his products without FDA supervised clinical trials.<ref name=1994judgement/> Burzynski appealed the limitations on his advertising on the grounds of free speech, but the appeal court upheld the decision, stating that "Burzynski's commercial speech does not concern a lawful activity."<ref name=opinion/> Burzynski was also found guilty of fraud in 1994, as he claimed reimbursement from a [[health insurer]] for a cancer treatment administered illegally.<ref name=1994judgement>[ftp://www.ca5.uscourts.gov/pub/93/93-02071.CV0.wpd.pdf No. 93-2071] July 28, 1994. United States Court of Appeals, Fifth Circuit summary judgment.</ref>
  
−
Burzynski had a hearing with the Texas Medical Board in April 2012. The FDA had put a partial clinicaö hold on Burzynski's clinical trials for pediatric patients which even was extended to all clinical trials six months later. FDA inspections of both Burzynski Clinic and Burzynski Research Institute followed in early 2013. However, FDA lifted these bans again in June 2013, despite damning inspection results establishing a rather sweeping non-compliance with FDA constraints by Burzynski. Meanwhile, the Texas Medical Board is again taking action against Burzynski. One of the latest additions to the list of trangressions, the TMB added the use of health care providers with little or no education or skill and representing them to patients as being doctors.<ref>http://www.sciencebasedmedicine.org/the-texas-medical-board-vs-stanislaw-burzynski-2014-edition/ </ref>
+
Burzynski had a hearing with the Texas Medical Board in April 2012. The FDA had put a partial clinical hold on his clinical trials for pediatric patients which even was extended to all clinical trials six months later. FDA inspections of both Burzynski Clinic and Burzynski Research Institute followed in early 2013. However, FDA lifted these bans again in June 2013, despite damning inspection results establishing a rather sweeping non-compliance with FDA constraints by Burzynski. Meanwhile, the Texas Medical Board is again taking action against Burzynski. One of the latest additions to the list of trangressions, the TMB added the use of health care providers with little or no education or skill and representing them to patients as being doctors.<ref>http://www.sciencebasedmedicine.org/the-texas-medical-board-vs-stanislaw-burzynski-2014-edition/ </ref>
  
 
Main Article:
 
Main Article:

Latest revision as of 10:45, 17 December 2014

Stanisław Burzyński

Stanislaw Rajmund Burzynski (born January 23, 1943 in Lublin, Poland) is a biochemist and a physician. He is the founder, president, and chairman of Burzynski Research Institute Inc. , based in Houston and Stafford, Texas. Since December 1976, Burzynski administered peptides and their metabolites, which he calls antineoplastons, as a treatment against cancer.

Legal Issues

In 1993, Burzynski was brought to court in Texas for treating patients with a therapy not approved by the Food and Drug Administration (FDA) and for selling antineoplastons in interstate commerce.[1][2] In 1998 the Texas Attorney General, Dan Morales, placed limits on his advertising of antineoplastons[3] and ordered him to cease and desist selling his products without FDA supervised clinical trials.[4] Burzynski appealed the limitations on his advertising on the grounds of free speech, but the appeal court upheld the decision, stating that "Burzynski's commercial speech does not concern a lawful activity."[1] Burzynski was also found guilty of fraud in 1994, as he claimed reimbursement from a health insurer for a cancer treatment administered illegally.[4]

Burzynski had a hearing with the Texas Medical Board in April 2012. The FDA had put a partial clinical hold on his clinical trials for pediatric patients which even was extended to all clinical trials six months later. FDA inspections of both Burzynski Clinic and Burzynski Research Institute followed in early 2013. However, FDA lifted these bans again in June 2013, despite damning inspection results establishing a rather sweeping non-compliance with FDA constraints by Burzynski. Meanwhile, the Texas Medical Board is again taking action against Burzynski. One of the latest additions to the list of trangressions, the TMB added the use of health care providers with little or no education or skill and representing them to patients as being doctors.[5]

Main Article: Antineoplaston

Links

References

  1. ↑ 1.0 1.1 Texas State Board of Medical Examiners, Appellant v. Stanislaw R. Burzynski, M.D., Ph.D., Appellee Court judgement
  2. ↑ Cite error: Invalid <ref> tag; no text was provided for refs named openjurist1987
  3. ↑ Template:Cite web
  4. ↑ 4.0 4.1 No. 93-2071 July 28, 1994. United States Court of Appeals, Fifth Circuit summary judgment.
  5. ↑ http://www.sciencebasedmedicine.org/the-texas-medical-board-vs-stanislaw-burzynski-2014-edition/
Retrieved from "https://www.psiram.com/en/index.php?title=Stanisław_Burzyński&oldid=2636"